Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SQUIBB, LEDERLE, WARNER CHILCOTT, GENEVA GENERICS

Executive Summary

SQUIBB, LEDERLE, WARNER CHILCOTT, GENEVA GENERICS (Ciba-Geigy) are among Bolar customers that have been affected by a recent round of Class II recalls involving 12 drug entities. The recalls were attributed by FDA to a lack of assurance that the products were "manufactured in conformity with conditions approved in the ANDAs." Although Bolar announced on Feb. 16 that it was recalling 13 additional drugs, FDA only just began to list the recalls in its "Enforcement Reports" (see listing below). Bolar initiated the recalls as a result of an ongoing audit of its applications and manufacturing processes ("The Pink Sheet" Feb. 19, p. 12). In September/October, Lederle suspended generic drug supply agreements with Bolar, Par, and four other companies caught up in the generic drug scandal ("The Pink Sheet" Nov. 6, T&G-15). Some of the Bolar products, however, were still in distribution channels at the time of the February recall.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS017313

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel